SCHEMBL60214

SCHEMBL60214

O=C(O)N(c1ccccc1)c1cccc(C(F)(F)F)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS2R14 Q9NYV8 2/20 0.43
P2RX7 Q99572 1/20 0.42
NPSR1 Q6W5P4 2/20 0.40
RXRA P19793 1/20 0.39
RXRB P28702 1/20 0.39
OPRM1 P35372 6/20 0.38
SIGMAR1 Q99720 5/20 0.38
KCNH2 Q12809 3/20 0.38
AHR P35869 1/20 0.38
PGK1 P00558 1/20 0.38
PGK2 P07205 1/20 0.38
KDM4E B2RXH2 1/20 0.36
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
JAK2 O60674 1/20 0.36
CCR6 P51684 1/20 0.36
ACLY P53396 1/20 0.35
NPC1 O15118 1/20 0.35
ALDH1A1 P00352 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL743478 0.77 NPSR1 (0.45) P2RX7NPSR1KDM4EKMT2AMEN1
SCHEMBL57998 0.76 NPSR1 (0.44) NPSR1KMT2AMEN1NPC1ALDH1A1
SCHEMBL4279593 0.75 HDAC4 (0.43) P2RX7NPSR1RXRARXRBALDH1A1
SCHEMBL1941770 0.73 KDM4E (0.46) NPSR1RXRARXRBKDM4EKMT2A
SCHEMBL743035 0.72 NPSR1 (0.40) NPSR1KMT2ANPC1ALDH1A1POLB
SCHEMBL4284245 0.71 HDAC4 (0.44) TAS2R14NPSR1RXRARXRBKDM4E
SCHEMBL14300714 0.71 PTGIR (0.55) NPSR1KDM4EKMT2ANPC1ALDH1A1
SCHEMBL57464 0.70 POLQ (0.40) NPSR1KMT2AMEN1HTTRAB9A
SCHEMBL10855054 0.69 NPSR1 (0.50) NPSR1KDM4EKMT2AMEN1NPC1
SCHEMBL2097683 0.69 NPSR1 (0.48) NPSR1KMT2ANPC1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829185-B2 Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis BAYER HEALTHCARE LLC (US) 2014-09-09 US disclosed
US-8338595-B2 Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis BAYER HEALTHCARE LLC (US) 2012-12-25 US disclosed
US-20120165314-A1 SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS BAYER HEALTHCARE LLC (US) 2012-06-28 US disclosed
US-8143393-B2 Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis BAYER HEALTHCARE LLC (US) 2012-03-27 US disclosed
US-8133995-B2 Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis BAYER HEALTHCARE LLC (US) 2012-03-13 US disclosed
US-20100063038-A1 Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis BAYER HEALTHCARE LLC 2010-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063038-A1 Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis CDK4, CDKL4, MKI67 TAS2R14 3635/4885P2RX7 1279/4885NPSR1 2883/4885
US-20120165314-A1 SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS CDK4, FLT4, CDKL4 TAS2R14 3653/4885P2RX7 1818/4885NPSR1 2879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.